Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DENN domain-containing protein 1A (DENND1A) is a protein that functions as a guanine nucleotide exchange factor (GEF) for the small GTPase Rab35, regulating clathrin-mediated endocytosis and vesicular trafficking[2][3][4]. It is characterized by an N-terminal DENN domain, along with binding motifs for clathrin, clathrin adaptor protein-2 (AP-2), and Src homology 3 (SH3) domains[1][2]. DENND1A is highly expressed in brain and testis and plays a crucial role in the endosomal recycling process[2][3]. Genetic variations and aberrant expression, especially of the truncated DENND1A.V2 isoform, have been associated with polycystic ovary syndrome (PCOS) via increased steroidogenic enzyme gene expression and androgen biosynthesis in ovarian theca cells[1][4]. While mechanistic insights implicate DENND1A in the pathogenesis of PCOS, no drugs are currently approved to target it directly[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DENN domain-containing protein 1A (DENND1A).